With CMTA support of $74,000, researchers at the University of Wisconsin-Madison, led by CMTA Strategy...
Development of a Human-Derived Myelin-Containing Organoid as a Reference Model for CMT1A
With CMTA support, researchers at the University of Antwerp, led by Vincent Timmerman, PhD, are...
Gene Editing Strategies for Demyelinating CMT
CMTA-supported researchers are advancing CRISPR-based gene editing for CMT1A and CMT1B, laying the foundation for mutation-specific therapies.
Nanoparticle-Based Gene Delivery to Schwann Cells for Treating CMT Disease
With joint funding of $299,992 from CMTA and the Muscular Dystrophy Association (MDA), researchers at...
Testing New UPR-Targeted Therapies for CMT1B
Researchers at the Ospedale San Raffaele (OSR) Scientific Institute in Milan, Italy, supported by the...
Schwann Cell-Targeted Gene Therapy Approaches to Treat CMT1A and Other Demyelinating Neuropathies
With CMTA support of over $160,000, an international team of researchers is developing genetic therapy...
Development of a new CMT1A research toolbox: an alternative human stem cell-based strategy
With CMTA support of $98,890, researchers at Hasselt University in Belgium, led by Esther Wolfs,...
1B Biomarkers and Outcome Measures
With CMTA support of $529,971, an international team of researchers from the Inherited Neuropathy Consortium,...
